Nagrestipen (ECI 301) (i.v; 2 μg; daily for 5 days) significantly inhibits tumor growth at 6 Gy local irradiation of tumor sites and enhances the distant septal effect of radiation in male BALB/c mice[1].
Nagrestipen (ECI 301) (i.v; 0.08, 0.4, 2 μg; day 1,8,15) can inhibit tumor growth in a dose-dependent manner at both irradiated and unirradiated sites of female C57BL/6 with LLC cells[1].
| Animal Model: | Male BALB/c mice with Colon26 cells and MethA cells[1] |
| Dosage: | 2 μg |
| Administration: | Intravenous injection; daily for 5 days |
| Result: | Significantly inhibited tumor size without significant toxicity.
Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated. |
